..............ProtoKinetix Receives Independent Confirmation of AAGP Anti-Inflammatory Action PROTOKINETIX INC. (PKTX: OTCBB ProtoKinetix Inc. (OTC Bulletin Board: PKTX), a biotech company focused on the research, development and commercialization of patented anti-aging glycopeptides (AAGPs(TM)) announced today that its Director of Science Dr. Geraldine Deliencourt has received results of tests conducted by a major independent laboratory in France to determine the biological activity of AAGP(TM) on the selectin inflammation pathway. The highly specific tests conducted on selectin showed 100% adhesion inhibition. Diseases such as Alzheimer's, Chron's, diabetes, arthritis, cancer and cardiovascular problems are among the many life-threatening conditions treated with anti-inflammation and selectin inhibition therapies. These results are consistent with previous tests conducted using extremely hostile stresses. Repeatedly, the presence of AAGP(TM) has shown its ability to protect cells under the most adverse of conditions. Dr. Deliencourt said, 'The results obtained broaden the impact and scope of the applications of AAGP(TM). They will also help us clarify the mechanism of action of AAGP(TM) and seem to be consistent with all of the previous results we have obtained.' She further explains that these results indicate that AAGP(TM) could be both an adhesion inhibitor and an anti-oxidant. Ross Senior, President and CEO of ProtoKinetix, said, 'The control of inflammation is of vital importance to the treatment of a number of immune complex mediated diseases. AAGP(TM) continues to demonstrate its potential to become a major contributor in the successful treatment of a wide range of health problems.'

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ProtoKinetix (OTCBB:PKTX.ob - News) (www.protokinetix.com ), a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine, biotechnology and cosmetic industries stated that it has repeatedly demonstrated the ability of their AAGP™ molecule to protect against the attacks of the most hostile inflammation causing agents known. Chronic and acute inflammation is the cause of countless diseases and premature death. As a result, containment, control or prevention of inflammation is, without question, one of the most important, universal health care objectives.

In the short term, ProtoKinetix is undertaking a series of independent tests towards the development of a disease specific therapeutic program. ProtoKinetix is embarking on the structuring of a partnership / licensing agreement to develop treatments for autoimmune diseases and chronic conditions. As an example, the inflammation of the pancreatic cells that produce insulin is now recognized as the cause of Diabetes.

This new direction of focus for ProtoKinetix has been made possible by the successful economic scale up of production of AAGP™ and the evaluation of the extensive testing done to date. The Company will now be in a position to better satisfy the testing demands throughout the world.

To date, medicine had limited options available in the treatment and containment of chronic inflammation. ProtoKinetix strongly believes that the AAGP™ family of molecules will prove to be a powerful therapeutic agent against all inflammatory diseases.